

Please type a plus sign (+) inside this box →



OCT 30 2002  
COPY OF PAPERS  
ORIGINAL FILED  
TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	09/914,364
				Filing Date	August 24, 2001
				First Named Inventor	Wacher
				Group Art Unit	Not yet available
				Examiner Name	Not yet available
Sheet	1	of	5	Attorney Docket Number	AVMX-008/02US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	P1	5,156,842		Mulligan	10/20/92
	P2	5,567,592		Benet et al.	10/22/96
	P3	5,665,386		Benet et al.	09/9/97
	P4	4,310,543		Gallo-Torres et al.	01/12/82
	P5	4,716,173		Salatinjants	Dec. 29, 1987
	P6	3,282,789		Bernard et al.	Nov. 1, 1966

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	F1	WO	95,20980			10.08.95	
	F2	EP	0 295 941 B1			21.12.88	
	F3	EP	0 314 384 A2			03.05.89	
	F4	EP	0 184 942 A2			18.06.86	
	F5	WO	WO 96/01128			Jan. 18, 1996	
	F6	GB	GB 997,914			July 14, 1965	
	F7	WO	WO 96/40192			Dec. 19, 1996	

Examiner Signature		Date Considered	11/3/03
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>2</sup> See attached Kinds of U.S. Patent Documents.


<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →



COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED  
OCT 30 2002  
TECH CENTER 1600/2900  
PTO/SB/

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
No copy	D1	Apostolides, Z., et al., "Inhibition of P450 mutagenicity by catechins, and by theaflavins and gallate esters," <u>Cancer Research</u> , 389(2-3):167-172 (1997)		
	D2	Baer-Dubowska, W., et al., "Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds," <u>Xenobiotica</u> , 28(8):735-43 (1998)		
No copy	D3	Bamforth, K.J., et al., "Common food additives are potent inhibitors of human liver 17 $\alpha$ -ethinyloestradiol and dopamine sulphotransferases," <u>Biochem. Pharmacol.</u> , 46(10):1713-1720 (1993)		
"	D4	Bonkovsky et al., "Cytochrome P <sub>450</sub> of Small Intestinal Epithelial Cells," <u>Gastroenterology</u> , 88:458-467 (1985)		
"	D5	Bourri�, M., et al., "Cytochrome P450 Isoform Inhibitors as a Tool for the Investigation of Metabolic Reactions Catalyzed by Human Liver Microsomes," <u>J. Pharmacol. Exp. Ther.</u> , 277(1):321-332 (1996)		
"	D6	Bradford, M.M., "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding," <u>Anal. Biochem.</u> , 72:248-254 (1976)		
"	D7	Burke, M. D., et al., "Ethoxy-, Pentoxy and Benzyloxyphenoxazones and Homologues: A Series Of Substrates To Distinguish Between Different Induced Cytochromes P-450," <u>Biochem. Pharmacol.</u> , 34(18):3337-3345 (1985)		
"	D8	Clarke, S.E., et al., "Characterization of the inhibition of P4501A2 by furafylline," <u>Xenobiotica</u> , 24:517-26 (1994)		
"	D9	Fabre, G., et al., "Evidence of CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions," <u>Drug Metab. Dispos.</u> , 21(6):978-985 (1993)		
"	D10	Fasco et al., "Rat Small Intestinal Cytochromes P450 Probed by Warfarin Metabolism," <u>Mol. Pharmacol.</u> , 43:226-233 (1993)		
"	D11	Gonzalez, F.J., et al., "Human P450PCN1: Sequence, Chromosome Localization, and Direct Evidence through cDNA Expression That P450PCN1 Is Nifedipine Oxidase, <u>DNA</u> ," 7(2):79-86 (1988)		
"	D12	Greenblatt, David J., "Presystemic Extraction: Mechanisms and Consequences," <u>J. Clin. Pharmacol.</u> , 33:650-656 (1993)		
No copy	D13	Kaminsky et al., "Small Intestinal Cytochromes P450," <u>Toxicology</u> , 21(6):407-422 (1992)		

No Copy	D14	Kedderis, G.L., et al., "Characterization of the N-Demethylation Reactions Catalyzed by Chloroperoxidase," <u>Microsomes, Drug Oxid., Chem. Carcinog., Int. Symp. Microsomes Drug Oxid.</u> , 1:351-4, <u>Public Academic Press</u> , eds. Coon, et al. (1980)	ORIGINAL FILED
"	D15	Kedderis, G.L., et al., "N-Demethylation Reactions Catalyzed by Chloroperoxidase," <u>J. Biol. Chem.</u> , 255(21):10174-82 (1980)	
"	D16	Kelleher, J., et al., "Modification of Paracetamol Hepatotoxicity by Anti-Oxidants," <u>J. Ind. Med. Res.</u> , 4 suppl.(4):138-144 (1976)	
"	D17	Kelleher, J., et al., "Modification of Paracetamol Toxicity by Antioxidants," <u>Biochem. Soc. Transact.</u> , 4:292-294 (1976)	
"	D18	Kivistö, K.T., et al., "Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole," <u>Clin. Pharmacol. Ther.</u> , 62(3):348-354 (1997)	
"	D19	Kolars, J.C. et al., "Identification of Rifampin-Inducible P450III A4 (CYP3A4) in Human Small Bowel Enterocytes," <u>J. Clin. Investig.</u> , 90:1871-1878 (1992)	
"	D20	Kolars et al., "Heterogeneity of Cytochrome P450IIIA Expression in Rat Gut Epithelia," <u>Gastroenterology</u> , 102:1188-1198 (1992)	
"	D21	Komori et al., "Cytochrome P-450 in Human Liver Microsomes: High-Performance Liquid Chromatographic Isolation of Three Forms and Their Characterization," <u>J. Biochem.</u> , 104:912-16 (1988)	not considered
"	D22	Kronbach et al., "Cyclosporine Metabolism in Human Liver: Identification of a Cytochrome P-450III Gene Family as the Major Cyclosporine-Metabolizing Enzyme Explains Interactions of Cyclosporine with Other Drugs," <u>Clin. Pharmacol. Ther.</u> , 43(6):630-5 (1988)	
"	D23	Leemann, T., et al., "Cytochrome P450TB (CYP2C): A Major Monooxygenase Catalyzing Diclofenac 4'-Hydroxylation in Human Liver," <u>Life Sciences</u> , 52:29-34 (1992)	
"	D24	Lilja, J.J., et al., "Grapefruit juice substantially increases plasma concentrations of buspirone," <u>Clin. Pharmacol. Ther.</u> , 64(6):655-660 (1998)	
"	D25	Lown, K.S., et al., "Sequences of Intestinal and Hepatic Cytochrome P450 3A4 cDNAs are Identical," <u>Drug Metab. Dispos.</u> , 26(2):185-187 (1998)	
"	D26	Lucas, D., et al., "Chlorzoxazone: An in Vitro and in Vivo Substrate Probe for Liver CYP2E1," <u>Methods in Enzymology</u> , 272:115-123 (1996)	
"	D27	Miller, C., et al., "Modulation of the mutagenicity and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by phenolic compounds," <u>Mutation Research</u> , 368(3-4):221-233 (1996)	
"	D28	Nash, "The Colorimetric Estimation of Formaldehyde by Means of the Hantzsch Reaction," <u>Biochem. J.</u> , 55:416-421 (1953)	
"	D29	Nelson, D. R., et al., "P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature," <u>Pharmacogenetics</u> , 6:1-42 (1996)	
No Copy	D30	Newton, D.J., et al., "Cytochrome P450 Inhibitors: Evaluation of Specificities in the In Vitro Metabolism of Therapeutic Agents by Human Liver Microsomes," <u>Drug Metabolism and Disposition</u> , 23(1):154-158 (1995)	
(5)	D31	Obermeier et al., "Effects of Bioflavonoids on Hepatic P450 Activities," <u>Xenobiotica</u> , 25(6):575-584, (1995)	

CIPE  
FEB 25 2002  
PATENT & TRADEMARK OFFICE

TECH CENTER 1600/2900

OCT 8 0 2002

RECEIVED

TECH CENTER 1600/2900

NO Copy	32	Mura, T., et al., "The Carbon Monoxide-Binding Pigment of Liver Microsomes II. Solubilization, Purification and Properties," <u>J. Biol. Chem.</u> , 239:2370-2378 (1964)
"	D33	Schmiedlin-Ren et al., "Cultured Adult Rat Jejunal Explants as a Model for Studying Regulation of CYP3A," <u>Biochem. Pharmacol.</u> , 46(5):905-918 (1993)
"	D34	Somberg et al., "The Clinical Implications of First-Pass Metabolism Treatment Strategies for the 1990's," <u>J. Clin. Pharmacol.</u> , 33:670-673 (1993)
O I P E FEB 25 2002 PATENT & TRADEMARK OFFICE	D35	Straehl, P., et al., "Isosorbide 5-Mononitrate and Isosorbide 2-Mononitrate Kinetics after Intravenous and Oral Dosing," <u>Clin. Pharmacol. Ther.</u> , 36(4):485-492 (1985)
"	D36	Straehl, P., et al., "Isosorbide Dinitrate Bioavailability, Kinetics, and Metabolism," <u>Clin. Pharmacol. Ther.</u> , 38(2):140-149 (1985)
"	D37	Stuckey, Ben N., "Antioxidants as Food Stabilizers," <u>CRC Handbook of Food Additives</u> , 2 <sup>nd</sup> ed., pp. 185-199 (1980)
"	D38	Tam, Yun K., "Individual Variation in First-Pass Metabolism," <u>Clin. Pharmacokinet.</u> , 25(4):300-328 (1993)
RECEIVED OCT 30 2002	D39	Trivier et al., "Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report)," <u>Life Sci.</u> , 52:PL91-96 (1993)
"	D40	van Hoogdalem et al., "Intestinal Drug Absorption Enhancement: An Overview," <u>Pharmacol. Ther.</u> , 44:407-443 (1989)
"	D41	Wacher, V. J., et al., "Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptides and Peptidomimetics," <u>Journal of Pharmaceutical Sciences</u> 87(11):1322-1330 (1998)
NO Copy	D42	Wang et al., "Interaction of Epicatechins Derived from Green Tea with Rat Hepatic Cytochrome P-450," <u>Drug Metabolism and Disposition</u> , 16(1):98-103, (1988)
"	D43	Watkins et al., "Identification of Glucocorticoid-Inducible Cytochromes P-450 in the Intestinal Mucosa of Rats and Man," <u>J. Clin. Invest.</u> , 80:1029-36 (1987)
"	D44	Watkins et al., "The Role of Cytochromes P-450 in Cyclosporine Metabolism," <u>J. Am. Acad. Dermatol.</u> , 23:1301-1309 (1990)
"	D45	Watkins et al., "Drug Metabolism by Cytochromes P450 in the Liver and Small Bowel," <u>Gastrointestinal Pharmacology</u> , 21(3):511-527 (1992)
"	D46	Weinke, S., et al., "Effect of four synthetic antioxidants on the formation of ethylene from methional in rat liver microsomes," <u>Toxicology Letters</u> , 35:247-251 (1987)
"	D47	WHO Food Additives Series, Vol. 32:3-23 (1993), Abstract
"	D48	World Health Organization, "Evaluation of certain food additives and contaminants," Pamphlet #837, pp.6-7, Geneva (1993)
NO Copy	D49	Wrighton et al., "Demonstration in Multiple Species of Inducible Hepatic Cytochromes P-450 and their mRNAs Related to the Glucocorticoid-Inducible Cytochrome P-450 of the Rat," <u>Molecular Pharmacology</u> , 28:312-321 (1985)

COPY OF PATENTS  
RECEIVED  
FILED

Not considered

Not considered

No copy	D50	Wrighton et al., "Studies on the Expression and Metabolic Capabilities of Human Liver Cytochrome P450IIIA5 (HLP3)," <u>Mol. Pharmacol.</u> , 38:207-213 (1990)	
4 O I P E FEB 27 5 2002 PATENT & TRADEMARK OFFICE	D51	Wu et al., "Use of IV and Oral Drug Levels from Cyclosporine (CsA) with Concomitant Rifampin to Differentiate Gut Absorption and Metabolism," <u>Pharm. Res.</u> 10; Abstract # PPDM 8185 (1993)	
	D52	Yang et al., "Inhibition of Hepatic Mixed Function Oxidase Activity by Propyl Gallate," <u>Biochem. Pharmacol.</u> , 23:3129-3138 (1974)	
	D53	Abstract for Japanese Patent No. JP 0220 2813 A JP, (August 28, 1993)	
No copy	D54	Abstract for Japanese Patent No. JP 0220 2813 A2, (August 10, 1990)	
	D55		
	D56		

Examiner Signature	<i>BA</i>	Date Considered	11/3/03
-----------------------	-----------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>2</sup> Applicant is to place a check mark here if English language Translation attached.

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED  
OCT 30 2002  
TECH CENTER 1600/2900